Lorazepam reduces recurrence of urethral obstruction in male cats: a prospective, randomized, double-blinded, placebo-controlled study.

Lorazepam safely reduces UO recurrence in male cats from 15.7% to 0%.

This prospective, randomized, double-blinded, placebo-controlled study evaluated lorazepam efficacy in reducing urethral obstruction (UO) recurrence in male cats. Eighty client-owned male cats presenting with first-time UO were enrolled between 2021-2025, with 64 completing the study (41 lorazepam, 39 placebo). Cats received treatment for one month post-hospitalization. Results demonstrated zero UO recurrence in the lorazepam group versus 15.7% in placebo recipients, a statistically significant difference. Lower urinary tract signs were reduced in 2 of 33 cats (days 8-15) and 1 of 31 cats (days 16-30) in the lorazepam group. Ataxia was the primary adverse effect, occurring in 13% of treated cats, with additional reported effects including sedation, increased appetite, and vocalization. The study concludes that lorazepam administration is safe and effective for reducing both recurrent UO and associated lower urinary tract signs in male cats following initial obstruction relief.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.